{"DataElement":{"publicId":"7461723","version":"1","preferredName":"Adverse Event Adverse Event Toxicity Grade Cytokine Release Syndrome Grade","preferredDefinition":"An indicator for the Cytokine Release Syndrome grade using the LEE scale.","longName":"AE_AETOXGR_CRS","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6381886","version":"1","preferredName":"Adverse Event Adverse Event Toxicity Grade","preferredDefinition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._The toxicity grade value of the adverse event.","longName":"2184272v1.0:6381884v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2184272","version":"1","preferredName":"Adverse Event","preferredDefinition":"An unwanted effect caused by a drug or therapy.  Such effects can be drug related, dose related, route related, patient related, caused by an interaction with another drug, or caused by opioid initiation or dose escalation.","longName":"Adverse Event","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-194E-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":"Change concept code to C41331 as C2861 is retired per EVS. dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6381884","version":"1","preferredName":"Adverse Event Toxicity Grade","preferredDefinition":"The toxicity grade value of the adverse event.","longName":"C78605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event Toxicity Grade","conceptCode":"C78605","definition":"The toxicity grade value of the adverse event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"727976DD-CBE2-7C51-E053-F662850AC07A","latestVersionIndicator":"Yes","beginDate":"2018-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-02","modifiedBy":"ONEDATA","dateModified":"2018-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"727976DD-CBF3-7C51-E053-F662850AC07A","latestVersionIndicator":"Yes","beginDate":"2018-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-02","modifiedBy":"MAESKEB","dateModified":"2020-05-27","changeDescription":"8/2/18 Created as part of CDISC mapping task; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6692798","version":"1","preferredName":"Cytokine Release Syndrome Grade","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening._A position on a scale of intensity or amount or quality.","longName":"CRS_GRADE","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"4","valueDescription":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","ValueMeaning":{"publicId":"6692799","version":"1","preferredName":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","longName":"6692799","preferredDefinition":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F8C-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FA5-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"3","valueDescription":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","ValueMeaning":{"publicId":"6692800","version":"1","preferredName":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","longName":"6692800","preferredDefinition":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FAF-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FC8-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"2","valueDescription":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","ValueMeaning":{"publicId":"6692801","version":"1","preferredName":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","longName":"6692801","preferredDefinition":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FD2-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FEB-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"1","valueDescription":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","ValueMeaning":{"publicId":"6692802","version":"1","preferredName":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","longName":"6692802","preferredDefinition":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FF5-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-700E-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6692797","version":"1","preferredName":"Cytokine Release Syndrome Grade","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.:A position on a scale of intensity or amount or quality.","longName":"C78251:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytokine Release Syndrome","conceptCode":"C78251","definition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F68-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F79-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"SETRAKIN","dateModified":"2019-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Cytokine Release Syndrome gra","type":"Preferred Question Text","description":"Cytokine Release Syndrome grade:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B12F9BB9-8FEF-3035-E053-4EBD850AE8F3","latestVersionIndicator":"Yes","beginDate":"2020-10-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-08","modifiedBy":"SETRAKIN","dateModified":"2020-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}